Data from the phase 1b TATTON study (NCT02143466) provided early evidence for the combination of osimertinib and savolitinib, a MET inhibitor, in patients with MET-amplified advanced NSCLC who progressed after receiving ≥1 first-, second-, or third-generation EGFR-TKIs (median duration of response 7.1 months, objective response rate (ORR] 52%)28,29, highlighting the importance of maintaining EGFR inhibition in subsequent lines of therapy. Here, MET is linked to non-small cell lung carcinoma.